According to several retrospective studies [6], meta-analyses [7] and post-hoc assessments of randomised trials [8], mammalian targeting of rapamycin (mTOR) inhibitors such as sirolimus (SRL) have been considered to be promising immunosuppressants for reducing the recurrence of HCC after LT [9]. Here, MTOR is linked to hepatocellular carcinoma.